Anti-B7-1/B7-2 antibody elicits innate-effector responses in macrophages through NF-kB-dependent pathway by Khan, Nooruddin et al.
International Immunology, Vol. 19, No. 4, pp. 477–486
doi:10.1093/intimm/dxm012
ª The Japanese Society for Immunology. 2007. All rights reserved.
For permissions, please e-mail: journals.permissions@oxfordjournals.org
Anti-B7-1/B7-2 antibody elicits innate-effector
responses in macrophages through
NF-kB-dependent pathway
Nooruddin Khan1, Sheikh Ghousunnissa1, SenthilKumar M. Jegadeeswaran1,
Dorairajan Thiagarajan2, Seyed E. Hasnain1,3,4 and Sangita Mukhopadhyay1
1Laboratory of Molecular Cell Biology Center for DNA Fingerprinting and Diagnostics, Hyderabad, India
2Indian Immunologicals Ltd, Hyderabad, India
3Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India
4University of Hyderabad, Hyderabad, India
Keywords: anti-B7-1/B7-2 mAb, autoimmunity, macrophage, NF-kappaB, TNF-alpha
Abstract
Blocking T cell co-stimulatory signals by anti-B7-1/B7-2 mAb is an attractive approach to treat
autoimmune diseases. However, anti-B7-1/B7-2 mAb treatment is known to exacerbate autoimmune
diseases through mechanisms not fully understood. Tumor necrosis factor alpha (TNF-a) and
reactive oxygen species (ROS) also play important roles in determining the clinical outcome of
autoimmune diseases. In this study, we demonstrate that the anti-B7-1 and the anti-B7-2 mAbs
activate macrophages for higher induction of TNF-a and other effector responses such as bacterial
cytotoxicity and production of ROS. Nuclear factor-kappaB (NF-kB) was found to be increased with
anti-B7-1/B7-2 mAb treatment. Inhibition of NF-kB activity by over-expression of phosphorylation-
defective I-kappaB alpha in anti-B7-1/B7-2 mAb-treated macrophages decreased TNF-a production.
These data indicate that anti-B7-1 and anti-B7-2 mAbs can trigger innate-effector responses in
macrophages by activating NF-kB-signaling pathway. Our results suggest that the B7 molecules are
not only essential for induction of adaptive immune responses but also play roles in activation of
innate immune responses.
Introduction
The Tcell activation is regulated by both the cognate peptide–
MHC-driven stimulus (1, 2) and the non-cognate co-stimulatory
signal (3–5). The B7 family of co-stimulatory molecules, the
B7-1 and the B7-2 of the antigen-presenting cells (APCs), in-
teract with CD28 receptors on T cells and provide major
non-cognate co-stimulatory signals (6, 7). Under certain patho-
physiological conditions, hyperactivation of Tcells through B7-1
and B7-2 often leads to development of autoimmunity
(8–11). Therefore, blocking the B7-1/B7-2 co-stimulatory
molecules with antibodies against them is an attractive way
to develop immunotherapeutics against autoimmunity (12, 13).
However, in some models of autoimmune disease, anti-B7-1/
B7-2 mAb therapy has yielded undesirable results (14–16). For
example, administration of anti-B7-1 mAb resulted in acceler-
ated onset of diabetes in the non-obese diabetic mice (15).
Similarly, it has been demonstrated that injection of anti-B7-1/
B7-2 mAb results in marked exacerbation of experimental aller-
gic encephalomyelitis (EAE) incidence (16).
Mechanisms by which the anti-B7-1/B7-2 mAb treatment
exacerbates autoimmune disease are not clear. Various
groups have shown that tumor necrosis factor alpha (TNF-a)
(17–25) and reactive oxygen species (ROS) (26, 27), pro-
duced by the activated APCs, are particularly involved in ex-
acerbation of autoimmune disease. It has been found that
mice with EAE when treated with combined anti-B7-1 and
anti-B7-2 mAbs had increased levels of TNF-a (16). This ob-
servation raises the possibility that anti-B7-1/B7-2 mAb ap-
plication can aggravate autoimmune disease possibly
through production of higher amounts of TNF-a. However, it
is not clear whether such higher level of the TNF-a produc-
tion is a consequence of macrophage hyperactivation in re-
sponse to anti-B7-1/B7-2 mAb treatment. Although some
forms of autoimmunity are linked to T cell production of TNF-a
(28), TNF-a and other inducible effector responses are
known to be regulated mainly by the macrophages (29–32).
Therefore, it is possible that these antibodies may activate
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TNF-a production by directly interacting with the B7-1/B7-2
molecules expressed on its surface. To test this hypothesis,
we examined whether interaction of B7-1 and B7-2 mole-
cules with respective mAbs could activate macrophages for
higher induction of TNF-a and other inducible effector
responses such as production of ROS, microbicidal activity
and signaling pathways involved.
Methods
Mice
BALB/c mice were bred and maintained in the animal facility
of Indian Immunologicals Ltd (IIL), Hyderabad, India. All
mice were 6–12 weeks old. All experimental procedures
were approved by the Institutional Review Committee for
care and usage of animals of IIL.
Macrophage stimulation assay
Peritoneal exudate cells (PECs) from BALB/c mice were har-
vested by injecting 4% thioglycolate broth as described
elsewhere (32). The RAW 264.7 macrophage cell line (H-2d)
was obtained from National Centre for Cell Science, Pune,
India. BMC2 macrophage cell line (H-2b) was a kind gift
from Satyajit Rath, National Institute of Immunology, New
Delhi, India. Both the macrophage cell lines were maintained
in DMEM (Invitrogen, Grand Island, NY, USA) containing
10% FCS (Invitrogen) and antibiotics (DMEM-10). Macro-
phages were either left untreated or treated with various
concentrations of either rat anti-mouse B7-1 mAb (clone
1G10, BD Biosciences PharMingen, San Diego, CA, USA)
or rat anti-mouse B7-2 mAb (clone GL1, BD Biosciences
PharMingen) and plated in 96-well tissue culture plate as 5
3 105 cells per well. Both anti-B7-1 mAb and anti-B7-2 mAb
were of IgG2a isotype. Therefore, in control samples, iso-
type-matched antibody of IgG2a type (BD Biosciences Phar-
Mingen) was added. In some experiments, macrophages
were activated with 3 lg ml1 of LPS (Sigma–Aldrich, St
Louis, MO, USA) and 3 ng ml1 of IFN-c (R&D Systems, Min-
neapolis, MN, USA) together (LPS + IFN-c) in the presence
of either IgG2a antibody or anti-B7-1/B7-2 mAb (BD Bio-
sciences PharMingen). After 48 h, culture supernatants were
harvested and assayed for TNF-a (BD Biosciences PharMin-
gen) induction. Endotoxin contamination in various samples
was removed by incubating samples with 10% v/v polymyxin
B–agarose (Sigma–Aldrich; binding capacity, 200–500 lg of
LPS from Escherichia coli serotype O128:B12 ml1) for 1 h
at 4C. After incubation, the agarose beads were removed
by centrifugation and the supernatant was filter sterilized
and used to stimulate macrophages. The F(ab#)2 fragments
were prepared using a commercially available F(ab#)2 prep-
aration kit (Cat. No. 44888) from Pierce Chemical Company
(Rockford, IL, USA). In brief, the samples were cleaved
using immobilized pepsin according to the manufacturer’s
protocol. Undigested Ig and Fc fragments were removed
by affinity chromatography with protein A–sepharose. The
fraction containing the F(ab#)2 fragments was collected and
dialyzed, examined by SDS–PAGE to verify removal of
non-digested IgG and Fc fragments, and used in the subse-
quent experiments.
Cytokine assay
The TNF-a, IL-10 and IL-12 cytokines in the macrophage
culture supernatants were quantified by two-site sandwich
enzyme-linked immunoassay (EIA) as described earlier (32,
33). Standard curve for the TNF-a/IL-10/IL-12 cytokine was
obtained using recombinant standard protein.
Western blotting
Western blotting was used to examine nuclear factor-
kappaB (NF-jB) levels in the nuclear extracts prepared from
macrophages treated with 10 lg ml1 of either IgG2a control
antibody or anti-B7-1 mAb or anti-B7-2 mAb. Nuclear
extracts prepared as described earlier (34) were separated
in a 10% SDS–PAGE under reducing conditions. Following
electrophoretic transfer to nitrocellulose membranes (Amer-
sham Biosciences, Little Chalfont, UK), the membranes were
incubated with affinity-purified goat antibodies to the NF-jB
family proteins p50 or p65 (Santa Cruz Biotechnology)
followed by incubation with anti-goat Ig–HRP conjugate
(Sigma–Aldrich). Blots were developed by chemiluminescence
using the manufacturer’s protocol (Amersham Biosciences).
Electrophoretic mobility shift assay
For electrophoretic mobility shift assay (EMSA), 10 lg of the
nuclear extracts prepared from various groups were incu-
bated for 30 min at 37C with 1 ng of 32P end-labeled com-
plementary oligo-deoxyribonucleotide containing the NF-jB
(35)-binding region (5#-TTGTTACAAGGGACTTTCCGCTGG-
GGACTTTCCAGGGAGGCGTGG-3# and 5#-CCACGCCTCC
CTGGAAAGTCCCCAGCGGAAAGTCCCTTGTAACAA-3#), 2
lg of poly (dI–dC) and a binding buffer (20 mM HEPES–KOH,
0.5 mM dithiothreitol, 1 mM MgCl2, 1 mM EDTA and 5% glyc-
erol). The DNA-protein complexes were resolved on a 7%
non-denaturing polyacrylamide gel in TGE-running buffer
(50 mM Tris–HCl of pH 7.5, 40 mM glycine and 10 mM
EDTA). The gel was dried and subjected to autoradiography.
Bactericidal assay
The bactericidal assay was performed as described (36). In
brief, macrophages treated with IgG2a or anti-B7-1/B7-2
mAb were incubated with live E. coli at a ratio of 1:10. After
15 min, cells were washed and incubated at various time
points in the presence of 10 lg ml1 gentamycin to kill all
extracellular bacteria. Cells were lysed with sodium deoxy-
cholate and the number of viable bacteria at each time point
for each group was determined by plating the lysates on LB
agar. Internalized bacteria were defined as those macro-
phage-associated bacteria that were viable after a 15-min
exposure and bacterial numbers, determined at subsequent
time points for each group, were expressed as percentage
of the internalized population.
Conditioned medium cytotoxicity on L929 cells
To assess biologic activity for the TNF-a produced by RAW
264.7 macrophages exposed to anti-B7-1/B7-2 mAb, L929
cytotoxicity assay was used (37). L929 cell line was a kind
gift from Satyajit Rath, National Institute of Immunology, New
Delhi, India. Cells were plated on 96-well plates at a density
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of 30 000 cells per well. After 24 h, mediumwas changed and 50
ll fresh medium and 50 ll of the medium collected from RAW
264.7 macrophages exposed to IgG2a control antibody or anti-
B7-1/B7-2 mAb were added in the presence of 1 lg ml1 actino-
mycin D. After 18 h, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) (Sigma–Aldrich) was added as 1
mg ml1 and incubated further for 5 h. Cells were then lysed
overnight using 100 ll of lysis buffer (20% SDS and 50% Dime-
thylformamide). Absorbance values were read at 550 nm.
All assays were carried out in triplicate, and data were com-
puted as mean 6 SD of five different experiments. Results are
expressed as the percentage of viable cells in relation to
supernatants from IgG2a-treated RAW 264.7 macrophages.
Total RNA isolation and reverse transcriptase–PCR
For reverse transcriptase (RT)–PCR, total RNA was isolated
from each sample using Trizol reagent as per the manufac-
turer’s (Invitrogen) protocol. Reverse transcription was car-
ried out using a GeneAmp RNA PCR core kit (Invitrogen).
PCR was performed at an annealing temperature of 58C
with the following primers: TNF-a forward primer (5#-CA-
GGGGCCACCACGCTCTTC-3#) and reverse primer (5#-CTT-
GGGGCAGGGGCTCTTGAC-3#), which generates a product
of 410 bp, and a house keeping gene b-actin forward primer
(5#-GTGGGCCGCTCTAGGCACCA-3#) and reverse primer
(5#-CGGTTGGCCTTAGGGTTCAGGGGGG-3#) which gener-
ates a product of 244 bp.
Dihydrorhodamine-123 fluorescence
Intracellular ROS level was measured with the use of fluores-
cence of rhodamine-123 produced from oxidation of dihy-
drorhodamine-123, as previously described (38). Briefly 5 3
105 cells were incubated at 37C with 10 lg ml1 of IgG2a
or anti-B7-1/B7-2 mAb for 1 h, followed by incubation with
15 lM dihydrorhodamine-123 for 45 min. Finally, the cells
were washed and embedded in Vectashield mounting me-
dium (Vector Laboratories, Burlingame, CA, USA). Micros-
copy was performed on a Nikon fluorescence microscope
(Nikon DX1, Japan).
Flow cytometry
For flow cytometry, macrophages were incubated with IgG2a
or anti-B7-1/anti-B7-2 antibody for 60 min. Heat-aggregated
rabbit sera were used at 1% concentration in the staining
buffer to block Fc receptors. After washing in staining buffer,
similar incubations were carried out for secondary reagent
(anti-rat FITC, Sigma–Aldrich). Stained cells were analyzed
on a Becton Dickinson flow cytometer (Becton Dickinson,
San Jose, CA, USA). Post flow cytometrical data analyses
were carried out using CellQuest data analysis software
(Becton Dickinson).
Transfection with phosphorylation-defective I-kappaB alpha
(DI-jBa) plasmid construct
The phosphorylation-defective I-kappaB alpha (I-jBa)
(DI-jBa) plasmid construct was a kind gift from Ju¨rgen
Heesemann (Max von Pettenkofer-Institut fu¨r Hygiene und
Medizinische Mikrobiologie, Mu¨nchen, Germany). Transfec-
tions were carried out with 10 lg of the DI-jBa construct
(39). Expression vector without any insert was used as nega-
tive control. The plasmid constructs were transfected into
RAW 264.7 macrophages using the cationic lipid suspension
lipofectin (Invitrogen). pSV-b-galactosidase (Promega, Madi-
son, WI, USA) vector was used for transfection efficiency
control. After 18 h, cells were stimulated with IgG2a control
antibody or anti-B7-1/B7-2 mAb. Cells were either harvested
after 1 h for the measurement of NF-jB activity in the nuclear
extracts by EMSA or for quantitation of b-galactosidase pro-
tein expression in the cytoplasmic extracts by b-galactosidase
ELISA (Roche Diagnostics, Penzberg, Germany) following the
manufacturer’s protocol or cultured for 48 h for estimation of
TNF-a levels secreted in the culture supernatants by EIA.
Statistical analysis
Data were expressed as mean 6 SD. Statistical compari-
sons were made using Mann–Whitney U-test. The signifi-
cance level was set at P < 0.05.
Results
Induction of TNF-a is higher in macrophages treated with
anti-B7-1/B7-2 mAb
We first examined whether murine macrophages treated
in vitro with mAb to either B7-1 or B7-2 produced higher
levels of TNF-a in the cultures. Accordingly, RAW 264.7 mac-
rophages were cultured with various concentrations (5, 10
and 15 lg ml1) of either isotype-matched control antibody
(IgG2a isotype) or anti-B7-1 mAb or anti-B7-2 mAb and after
48 h, culture supernatants were tested for the levels of TNF-
a produced by EIA. As opposed to the isotype control
group, treatment with the anti-B7-1 mAb resulted in in-
creased production of TNF-a for all treatment regimes
(Fig. 1A). Similarly, the anti-B7-2 mAb also increased TNF-a pro-
duction in RAW 264.7 macrophages (Fig. 1A). Since TNF-a
production in the group treated with IgG2a isotype antibody
even at 15 lg ml1 concentration was low and similar to that
produced by the group treated with medium alone (Fig. 1A,
compare bar 8 with bar 1), it can be concluded that specific
binding of B7-1/B7-2 molecules with its respective intact
mAb can trigger macrophages to produce TNF-a. An anti-
body concentration of 10 lg ml1 resulted in maximum
TNF-a induction in both the cases (Fig. 1A). Therefore, all
the following experiments were carried out using 10 lg ml1
anti-B7-1/B7-2 mAb. Both anti-B7-1 mAb and anti-B7-2 mAb
individually stimulated murine macrophages to preferentially
express mRNA transcripts for TNF-a as compared with the
IgG2a control group (Fig. 1B). We next examined whether
induction profile of TNF-a was directly proportional to the
number of B7-1/B7-2 molecules. Therefore, we stimulated
macrophages with LPS + IFN-c to increase B7-1 and B7-2
levels on macrophages as detected by flow cytometry
(Fig. 1C). These cells were then treated with 10 lg ml1
anti-B7-1/B7-2 mAb and TNF-a productions by these cells
were compared with the levels produced from macrophages
treated with anti-B7-1/B7-2 mAb only without LPS + IFN-c. It
could be seen that the TNF-a production was more in the
LPS + IFN-c-activated group (Fig. 1D) than those treated
with anti-B7-1/B7-2 mAb alone. To confirm that the observed
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data of increased TNF-a production by anti-B7-1/B7-2 mAb
was not due to endotoxin contamination in the antibody
preparations, the anti-B7-1 mAb and the anti-B7-2 mAb were
treated with heat (95C for 10 min), incubated with poly-
myxin B–agarose or added to the macrophage cultures that
were pre-treated with anti-CD14 plus anti-Toll-like receptor 4
(TLR4) antibody to block CD14 receptor and TLR4, specific
for LPS binding (40). It was found that the activity of anti-
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B7-1/B7-2 mAb on the production of TNF-a could be abro-
gated by heat but not by polymyxin B (Fig. 1E) or anti-CD14
plus anti-TLR4 antibody treatment (Fig. 1F). These results
rule out contribution of endotoxin to the macrophage stimu-
latory property of anti-B7-1/B7-2 mAb.
We have shown earlier that the macrophage effector func-
tions can be controlled at the level of MHC haplotype (35).
Therefore, using macrophage of H-2b haplotype (BMC2),
we examined whether the anti-B7-1/B7-2 mAb could en-
hance TNF-a production in H-2b macrophages (BMC2) to
a similar extent in H-2d macrophages (RAW 264.7). The
level of TNF-a produced in macrophages incubated with
IgG2a or anti-B7-1/B7-2 antibody was compared. It was evi-
dent that the anti-B7-1 mAb and the anti-B7-2 mAb at 10 lg
ml1 concentration enhanced TNF-a secretion also in H-2b
macrophages (Fig. 1G). This result suggests that anti-B7-1/
B7-2 mAb induces TNF-a in macrophages irrespective of
MHC haplotype. The anti-B7-1/B7-2 mAb at 10 lg ml1 con-
centration induced higher level of TNF-a also in PEC-derived
macrophages from BALB/c mice (Fig. 1G) indicating that
results obtained with transformed mouse macrophage cell
lines (RAW 264.7/BMC2) were equally true in primary cul-
tures of mouse macrophages.
It is already known that signaling through the Fc receptors
like CD32 and CD64 can activate macrophages for higher
production of TNF-a (41). To rule out this possibility, we next
treated anti-B7-1 and anti-B7-2 antibodies with pepsin to
remove the Fc portion and used the purified F(ab#)2 frag-
ments to cross-link B7-1 and B7-2 receptors. It was found
that the F(ab#)2 fragments activated macrophages for in-
creased TNF-a induction (Fig. 1H) in a similar manner as ob-
served with the respective intact antibody (Fig. 1A). These
results indicate that signaling through the B7-1/B7-2 activate
macrophages to produce TNF-a. It was noticed that although
TNF-a was increased, anti-B7-1/B7-2 mAb had little effect on
the induction profile of IL-10 and IL-12 cytokines (Fig. 1I).
Increased production of TNF-a by macrophages treated with
anti-B7-1/B7-2 mAb leads to enhanced cytotoxicity of
L929 cells
The capacity of anti-B7-1/B7-2 mAb to stimulate RAW 264.7
macrophages to secrete TNF-a was further assessed by L929
cytotoxic bioassay. L929, a murine fibrosarcoma cell line is
highly sensitive to the anti-proliferative and cytotoxic action of
TNF-a (37). L929 cells were incubated with media harvested
from the macrophage cultures treated either with IgG2a or
anti-B7-1/B7-2 mAb in the absence or presence of LPS + IFN-c.
The MTT assay shown in Fig. 2(A) reveals that ;50% of the
cells are dead when incubated with anti-B7-1/B7-2 mAb-
treated culture supernatants. In cells co-treated with LPS +
IFN-c, the cytotoxicity effect was further increased (Fig. 2A)
compared with anti-B7-1/B7-2 mAb treatment alone. Addition
of 10 lg ml1 of anti-TNF-a mAb in the culture assay inhibited
the observed cytotoxicity for all treatment regimes (Fig. 2B)
confirming that the cytotoxicity effect was due to the TNF-a.
These results correlate with the concentration of TNF-a present
in the supernatants (Fig. 1D) and additionally point to the bio-
logic activity for this cytokine.
Anti-B7-1/B7-2 mAb increases induction of ROS in
macrophages
TNF-a can augment ROS production in macrophages (42,
43). Intracellular ROS levels were therefore examined in the
Fig. 1. The anti-B7-1/B7-2 mAb stimulates macrophages for increased TNF-a production. The RAW 264.7 macrophages were either left
untreated or treated with various concentrations of either IgG2a or anti-B7-1/B7-2 antibody and after 48 h culture supernatants were tested for the
levels of TNF-a produced by EIA (A). Total RNA from macrophages stimulated with 10 lg ml1 of either IgG2a antibody or anti-B7-1 or anti-B7-2
mAb was subjected to RT–PCR analysis to determine induction of TNF-a mRNA with b-actin used as amplification control (B). RAW 264.7
macrophages were treated with LPS + IFN-c for either flow cytometric analysis of B7-1 and B7-2 co-stimulatory molecules (C) or for measuring
TNF-a production in the presence of IgG2a or anti-B7-1/B7-2 mAb (D). TNF-a induction was measured in RAW 264.7 macrophages incubated
with native, heat boiled (95C for 10 min) or polymyxin B-treated anti-B7-1/B7-2 mAb (E). In a separate experiment, anti-B7-1/B7-2 mAb-
mediated TNF-a induction was measured in macrophages pre-treated with anti-CD14 plus anti-TLR4 antibody (F). Also TNF-a was measured in
BMC2 or PEC-derived macrophages treated with IgG2a or anti-B7-1/B7-2 mAb (G). RAW 264.7 macrophages were treated with pepsin digested
F(ab#)2 fragments of IgG2a or anti-B7-1/B7-2 antibody for 48 h and the levels of TNF-a produced in the cultures were measured by EIA (H). RAW
264.7 macrophages were treated with IgG2a or anti-B7-1/B7-2 antibody and after 48 h culture supernatants were tested for the levels of IL-10
and IL-12 cytokines by EIA (I). Data are representative of five different experiments. The significance of the results of anti-B7-1/B7-2 mAb-
mediated induction of TNF-a at 10 lg ml1 (A, bar 6 and bar 7) was statistically determined using Mann–Whitney U-test by comparison with the
value of IgG2a control (bar 5). Similarly Mann–Whitney U-test was carried out for the data shown in bar 6 and bar 7 of (D and E) and compared
with their respective controls namely bar 5 of (D) and bar 3 and bar 4 of (E). **indicates P < 0.01.
Fig. 2. Enhanced cytotoxicity of L929 cells by culture supernatants
harvested from the macrophage cultures treated with anti-B7-1/B7-2
mAb. Centrifuged supernatants from RAW 264.7 macrophages
treated as described in Fig. 1D were transferred onto cultures of
L929 cells in the absence (A) or presence (B) of 10 lg ml1 of
neutralizing anti-TNF-a antibody. Cell viability was determined by MTT
assay. The viability of macrophages in the wells that received culture
supernatants from the IgG2a-treated group was considered to be
100% and viability of the test samples was monitored based on
percentage of normalized control. Data are representative of five
different experiments. The significance of the L929 cytotoxicity in (A)
was determined by statistical analysis using Mann–Wnitney U-test for
the data shown in bar 3, bar 4, bar 5 and bar 6 by comparison with
their respective controls. *indicates P < 0.05 and **indicates P < 0.01.
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anti-B7-1/B7-2 mAb-treated macrophages using rhodamine-
123 fluorescence assay based on the oxidation of dihydro-
rhodamine-123. It was evident that the anti-B7-1 mAb and
the anti-B7-2 mAb increased intracellular ROS levels in RAW
264.7 macrophages as compared with the IgG2a control
antibody (Fig. 3).
Macrophages treated with anti-B7-1/B7-2 mAb show
enhanced microbicidal function
Induction of ROS is critically important for macrophage-
mediated microbicidal activity (44, 45). The microbicidal
function of macrophages treated with either anti-B7-1 mAb
or anti-B7-2 mAb was therefore directly examined. Macro-
phages treated with either IgG2a (IgG2aM) or anti-B7-1
(B7-1M) or anti-B7-2 (B7-2M) antibody were incubated with
live E. coli for 15 min and cultured for various time points be-
fore lysis. The numbers of surviving bacteria in the lysates
were estimated by calculating the number of colony-forming
unit on LB-agar plates as described (36). It was observed
that the bactericidal ability of both B7-1M and B7-2M was
significantly higher than that of IgG2aM (Fig. 4A, compare
bar 2 and bar 3 with bar 1). After 3 h of incubation, the B7-
1M and the B7-2M reduced bacterial viability by over 50%
(Fig. 4A), while ;90% of the input bacteria were found to
be alive in the macrophage treated with IgG2a antibody. By
the end of 6 h, >90% of the input bacteria were killed in
B7-1 mAb- or B7-2 mAb-treated macrophages (Fig. 4B),
whereas ;55% of the input bacteria were alive in macro-
phages treated with IgG2a antibody. As expected, bacteri-
cidal activity of the macrophages treated with anti-B7-1/B7-2
mAb was still higher in the presence of LPS + IFN-c when ex-
amined after 3 h (Fig. 4C). These results demonstrate the
ability of anti-B7-1/B7-2 mAb-treated macrophages to display
enhanced microbicidal function.
Macrophages treated with anti-B7-1/B7-2 mAb show
increased induction of NF-jB
In the previous experiments (Figs 1, 2 and 4), we observed
that anti-B7-1/B7-2 mAb increased TNF-a induction and up-
regulated microbicidal activity of macrophages. The NF-jB
family of transcriptional regulators is important for induction
of TNF-a (32) as well as microbicidal activity (46). Therefore,
we examined if macrophages treated with anti-B7-1/B7-2
mAb showed increased induction of NF-jB as measured
by EMSA using a consensus NF-jB oligo-deoxynucleotide
probe (35) labeled with [c-32P]-ATP. As compared with the
IgG2a control group, intensity of the DNA-protein complex
corresponding to the NF-jB proteins was apparently in-
creased upon treatment of macrophages with either B7-1
mAb (Fig. 5A, compare lane 4 with lane 2) or B7-2 mAb
(Fig. 5A, compare lane 6 with lane 2). As expected, LPS +
IFN-c treatment increased intensity of the complex (Fig. 5A,
compare lanes 5 and 7 with 3). Homologous cold competi-
tion assay confirmed the specificity of the DNA-protein com-
plex (Fig. 5A, lane 8). Since p50 and p65 NF-jB play
important role in TNF-a gene activation (47, 48), we next
examined expression profile of p50 and p65 NF-jB in mac-
rophages treated with anti-B7-1/B7-2 mAb by western blot-
ting. While control macrophages (incubated with IgG2a
antibody) showed very little nuclear p50 and p65 NF-jB,
LPS + IFN-c-activated macrophages showed significant
induction of these proteins (Fig. 5B and C, compare lane
2 with lane 1). Treatment with anti-B7-1 mAb (Fig. 5B)
and anti-B7-2 mAb (Fig. 5C), as compared with the control
Fig. 3. The anti-B7-1/B7-2 mAb stimulates macrophages for the
production of ROS. RAW 264.7 macrophages were treated with 10 lg
ml1 of either IgG2a or anti-B7-1 mAb or anti-B7-2 mAb for 1 h. Cells
were then incubated with 15 lM dihydrorhodamine-123 for 45 min.
Cells were washed and assayed for immunofluorescence on a Nikon
fluorescence microscope. Data are representative of five different
experiments.
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population, resulted in an increase in p50 and p65 NF-jB
proteins (Fig. 5B and C, lane 3). As expected, LPS + IFN-c-
activated macrophages displayed very high expression of
NF-jB proteins during treatment with anti-B7-1/anti-B7-2
mAb (Fig. 5B and C, lane 4). These results convincingly
show that treatment of macrophages with anti-B7-1/anti-B7-
2 mAb results in increased NF-jB activity as evident from
EMSA and western blotting.
Inhibition of NF-jB activity by expression of the
phosphorylation-defective I-jBa (DI-jBa) results
in inhibition of TNF-a production in macrophages
exposed to anti-B7-1/B7-2 mAb
We next examined whether activation of NF-jB complex by
anti-B7-1/B7-2 mAb was actually responsible for increased
TNF-a induction in macrophages. The role of NF-jB pathway
in the activation of TNF-a in anti-B7-1/B7-2 mAb-treated
macrophages was confirmed by inhibiting NF-jB levels us-
ing phosphorylation-defective I-jBa (DI-jBa) plasmid con-
struct. The RAW 264.7 macrophages were co-transfected
with either backbone vector (PRC/CMV) or DI-jBa construct
along with b-galactosidase vector (pSV-b-galactosidase).
After 18 h of transfection, these macrophages were acti-
vated with 10 lg ml1 of either IgG2a or anti-B7-1/B7-2
mAb. It could be seen that as compared with the control
group (Fig. 6A, lane 2), both anti-B7-1 mAb (Fig. 6A, lane 3)
and anti-B7-2 mAb (Fig. 6A, lane 4) increased NF-jB levels
in macrophages (Fig. 6A, compare lanes 3 and 4 with lane
2). Transfection with DI-jBa inhibited nuclear levels of NF-jB
in macrophages treated with either anti-B7-1 mAb (Fig. 6A,
compare lane 6 with lane 3) or anti-B7-2 mAb (Fig. 6A, com-
pare lane 7 with lane 4). This reduction in NF-jB activity
in the DI-jBa transfected macrophages decreased TNF-a
production in response to treatment with either anti-B7-1
mAb (Fig. 6B, compare bar 5 with bar 2) or anti-B7-2 mAb
(Fig. 6B, compare bar 6 with bar 3). b-Galactosidase protein
expression was found to be equivalent in all the groups indi-
cating equal transfection efficiency (Fig. 6C). These data
demonstrate that NF-jB plays an important role in the induc-
tion of TNF-a in response to anti-B7-1/B7-2 mAb treatment.
Discussion
Blocking the B7-mediated co-stimulation is a promising tar-
get for therapeutic intervention in autoimmune diseases (12,
13). Although in human rheumatoid arthritis disruption of the
CD28 pathway with CTLA4–Ig is effective (49, 50), however,
administration of the anti-B7-1 mAb or the anti-B7-2 mAb
has been shown to exacerbate autoimmune diseases in vari-
ous murine model (13, 51). The mechanism underlying this
observation remains largely unknown. Therefore, under-
standing it is important. In the present in vitro study, we pro-
vide evidence that the anti-B7-1 mAb and the anti-B7-2
mAb but not the IgG2a isotype-matched antibody activate
macrophages for higher production of inflammatory mole-
cules, TNF-a and ROS. Since TNF-a and ROS are known to
trigger autoimmune disease (17–27), it is possible that anti-
B7-1/B7-2 treatment enhances autoimmune diseases by ex-
acerbating TNF-a–ROS production. The observation that
treatment of mice with anti-B7-1/B7-2 antibody results in in-
creased TNF-a level (16) supports the possibility that TNF-a
could be the causal factor for the EAE disease severity in
mice treated with anti-B7-1/B7-2 mAb. This study indicates
that in addition to provide non-cognate co-stimulatory sig-
nals to T cells, the B7-1 and the B7-2 molecules also provide
signals to macrophages for induction of innate-effector
responses, indicating that they are not only essential for in-
duction of adaptive immune responses but also play crucial
role in activating innate-effector responses.
The anti-B7-1/B7-2 mAb was found to affect the NF-jB
signaling in that the nuclear p50 and p65 NF-jB levels were
increased during cross-linking of the B7 ligands (B7-1 and
Fig. 4. Macrophages treated with anti-B7-1/B7-2 mAb show increased microbicidal activity. RAW 264.7 macrophages treated with 10 lg ml1 of
either IgG2a or anti-B7-1 or anti-B7-2 mAb were incubated with live Escherichia coli bacteria for 15 min. Bactericidal activity was monitored after
3 h (A) and 6 h (B). In another experiment, bactericidal assay was performed using macrophages treated with LPS + IFN-c plus IgG2a or LPS +
IFN-c plus anti-B7-1/B7-2 mAb (C). Data are representative of five different experiments. Statistical significance of these data was determined
using Mann–Whitney U-test by comparison with the respective controls. **indicates P < 0.01.
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B7-2) with the respective antibody. Induction of TNF-a by
anti-B7-1/B7-2 mAb was found to be dependent mainly
on NF-jB activation since inhibition of the NF-jB activity by
expression of the DI-jBa resulted in inhibition of TNF-a in-
duction in macrophages treated with anti-B7-1/B7-2 mAb.
Fig. 6. Transient expression of the phosphorylation-defective I-jBa
(DI-jBa) construct in the anti-B7-1/B7-2 mAb-treated macrophages
results in inhibition of both NF-jB and TNF-a induction. The RAW
264.7 macrophages co-transfected with either DI-jBa or mock
plasmid (PRC/CMV) along with b-galactosidase construct (pSV-b-
galactosidase) were treated with IgG2a or anti-B7-1/B7-2 mAb. NF-
jB levels were examined by EMSA (A) and TNF-a production by EIA
(B). The b-galactosidase expression was measured following b-
galactosidase ELISA (C). Data are representative of five different
experiments. Statistical significance of the data shown in bar 5 and
bar 6 of (B) was determined using Mann–Whitney U-test by
comparison with the respective controls. **indicates P < 0.01.
Fig. 5. Macrophages treated with anti-B7-1/B7-2 mAb show in-
creased NF-jB activity. RAW 264.7 macrophages were treated with
10 lg ml1 of IgG2a or anti-B7-1/B7-2 mAb in the absence or
presence of LPS + IFN-c. After 60 min, nuclear proteins were isolated
and binding reactions were carried out using a consensus NF-jB
oligonucleotide probe labeled with [c-32P]-ATP (A). Also nuclear
extracts were used to examine p65 (B and C, upper panels) and p50
(B and C, lower panels) NF-jB levels by western blotting. The same
membranes were stained with Ponceau S stain to confirm equal
loading of proteins. Results shown are representative of at least five
independent experiments.
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Although B7-1 and B7-2 molecules induce differential
responses in T cells (12, 52), our findings indicate that in
macrophages, however, these molecules probably elicit sim-
ilar responses. Since both anti-B7-1 and anti-B7-2 mAbs
triggered equivalent levels of TNF-a and ROS in macro-
phages, it is likely that the downstream-signaling cascades
triggered in response to stimulation through B7-1 molecules
are similar to that of B7-2 molecules. This is further sup-
ported by the fact that both anti-B7-1 and anti-B7-2 mAbs
could trigger NF-jB activation to almost similar extent in
macrophages.
It has been proposed that activation of macrophage in-
flammatory responses, namely the TNF-a, is a ‘danger sig-
nal’ for induction of autoimmune diseases (17–22). Our
studies suggest that anti-B7-1/B7-2 mAb therapy can prime
signals for the higher production of TNF-a and ROS from
macrophages and thus may contribute to disease severity
in various models of autoimmunity. Since B7-1/B7-2 mAb
activates induction of TNF-a as well as ROS and bactericidal
activity in macrophages, anti-B7-1/B7-2 mAb treatment can
be used to tailor immune responses to induce cytotoxicity
against intracellular pathogens (53, 54) that reside inside
the macrophages.
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APC antigen-presenting cell
EAE experimental allergic encephalomyelitis
EIA enzyme-linked immunoassay
EMSA electrophoretic mobility shift assay
IIL Indian Immunologicals Ltd
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